Jonathan Addison (BEc (Tas), ASIC, CFTP (Snr))
Chairman and Independent Director

Mr Addison has over 30 years in the investment management industry, including wide experience in superannuation.  Currently he is the Investment Manager (formerly Fund Manager) of the Meat Industry Employee Superannuation Fund (MIESF) whom he joined in June 1999 and where he is responsible for the investment management of MIESF.

MIESF, a self-administered industry superannuation fund established in 1981 which operates nationally, currently holds 21,800,000 shares in Phosphagenics Limited.  Prior to his appointment to MIESF, Mr Addison was a Director and Asset Consultant within the corporate finance section of PricewaterhouseCoopers and in this role was responsible for establishing an investment consulting practice with clients ranging from superannuation funds to insurance funds and funds managers.  Prior to that, he was Manager Investment Consultant at Sedgwick Noble Lowndes.

Mr Addison also holds Non-Executive Directorships with Austcorp Group Limited, Austcorp Funds Management Limited, African Enterprise Limited, African Enterprises New Zealand Limited, Hawksbridge Limited, Global Masters Fund Limited and TPCG Limited.

Mr Addison is the Chairman of the Company’s Audit, Compliance and Corporate Governance Committee.

Harry Rosen (BA, LLB)
President & Chief Executive Officer

Mr Rosen is one of the founders of Betatene Limited and Denehurst Ltd, two formerly ASX-listed companies which commercialised significant research and development.  Betatene is the world's largest producer of natural beta carotene.  After the purchase of Betatene Limited by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development.  As a Vice President of Henkel Corporation, he worked for a number of years in the US in the nutrition and health care industries.

Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies.  He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law.  Mr Rosen graduated from the Australian National University (BA-Psychology) and Melbourne University (LLB).

Esra Ogru (BSc(Hons), PhD)
Chief Executive Officer

Dr Ogru was appointed Joint CEO of Phosphagenics in April 2010.  As an Executive Director she is responsible for the strategic direction of the organisation, as well as oversight of operations and financial activities. She plays an active role in driving key development programs, commercial negotiations and general corporate activity. She leads a team of experienced pharmaceutical scientists, chemists and strategic collaborators.

In this role, Dr Ogru has developed commercial opportunities for both the Company’s nutraceutical division and pharmaceutical technologies, such as transdermal drug delivery and drug enhancement platforms for cancer, heart disease and chronic pain management.  Further, Dr Ogru has many years experience in both the academic and commercial aspects of the industry and has numerous publications in peer-reviewed journals.
 

Don Clarke
Independent Director

Mr Don Clarke has been a partner of law firm Minter Ellison since 1988.   He serves in the Melbourne Private Equity & Capital Markets group, predominantly advising ASX listed companies across a range of industries with emphasis on technology and manufacturing.

Mr Clarke is also the Deputy Chairman of Webjet Limited and a Director of Circadian Technologies Limited.  He previously served on the Board of Calzada Limited (formerly Metabolic Pharmaceuticals Limited).

Stuart James
Independent Director

Mr Stuart James has held a number of high profile executive positions during his career and has extensive experience in the oil, health, pharmaceutical and financial services sectors.  Following a 25 year career with Shell, both in Australia and internationally, Mr James past roles have included Managing Director of Australian Financial Services for Colonial Group and Managing Director of Colonial State Bank (formerly the State Bank of NSW). 

Mr James most recent executive role was as CEO of the Mayne Group, including Mayne Health and Mayne Pharma.  He is a Member of the Supervisory Board of Wolters Kluwer NV and a Member of the Advisory Board of Gresham Private Equity Ltd.  Mr James is Chairman of Pulse Health Ltd, Progen Pharmaceuticals Ltd, Prime Financial Group Ltd and a Non-Executive Director of Greencross Ltd.
 

Sandra Webb (BPharm, PhD, Dip Law)
Independent Director

Dr Sandra Webb rejoins Phosphagenics, having served with the company as Pharmaceutical Development Advisor from February 2005 to June 2006.  Dr Webb is a Director of Ground Zero Pharmaceuticals Pty Limited.  She previously served on the Boards of AusBiotech Limited, Amrad Corporation Limited and Quintiles Limited.

An experienced pharmaceutical professional, Dr Webb has a strong track record of achievements in the commercial world of drug development.  As Managing Director of Quintiles Australia, she successfully grew the company as the leading commercial research organisation in Australia.  Under her stewardship Quintiles Australia was the most profitable subsidiary of the worldwide Quintiles Transnational Inc.

Dr Webb’s research has been published in over 30 prestigious peer reviewed journals including the Journal of Physiology and the British Journal of Pharmacology and Nature.